CYDYOTCPharmaceutical PreparationsFiscal year ends May 31

CytoDyn Inc.

Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 14, 2026

$0.25+0.02 (+9.53%)

Close on Oct 19, 2026

Market cap: $345.56M
P/E (TTM): –
Dividend yield: –

Earnings

Quarterly results announced on Form 8-K, Item 2.02

No earnings releases found

CytoDyn has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.

Press releases

Announcements CytoDyn filed with the SEC

Apr 30, 2026, 4:32 PM ET
Leronlimab – A Novel Therapeutic in CCR5+ Immuno-Oncology CYTODYN.COM / OTCMKTS: CYDY
Regulation FD disclosure · EX-99.1 to Form 8-K
Nov 3, 2025, 8:38 AM ET
CytoDyn Secures $30 Million Commitment from Yorkville Advisors
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
May 6, 2025, 5:05 PM ET
CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Jul 9, 2024, 8:46 AM ET
CytoDyn Announces Settlement with Amarex Clinical Research LLC
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Jan 29, 2024, 8:40 AM ET
CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Nov 21, 2023, 5:15 PM ET
CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Nov 3, 2023, 5:41 PM ET
November 2023 Letter to Shareholders
Regulation FD disclosure · EX-99.1 to Form 8-K
Jul 11, 2023, 4:20 PM ET
CytoDyn Announces Company Updates and Investment Community Update Webcast
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
May 24, 2023, 5:15 PM ET
CytoDyn Announces President Takes Medical Leave of Absence
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Dec 7, 2022, 11:00 AM ET
CytoDyn – R&D Investor 1 Update December 7, 2022
Regulation FD disclosure · EX-99.1 to Form 8-K
Oct 28, 2022, 5:15 PM ET
CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Nov 24, 2021, 4:02 PM ET
November 24, 2021 Annual Meeting of
Regulation FD disclosure · EX-99.1 to Form 8-K
Nov 16, 2021, 7:46 PM ET
CytoDyn Reminds Stockholders to Register 24 hours before November 24 th Annual Meeting
Other events · EX-99.1 to Form 8-K
Oct 28, 2021, 1:57 PM ET
CytoDyn Inc. Announces Adjournment of Annual Meeting of Shareholders
Other events · EX-99.1 to Form 8-K
Oct 21, 2021, 4:06 PM ET
CytoDyn to Hold Webcast and Live Q/A on October 26
Other events · EX-99.1 to Form 8-K
Oct 20, 2021, 5:25 PM ET
CytoDyn Announces Delaware Court Has Denied Activist Group’s Motion to Prevent
Other events · EX-99.1 to Form 8-K
Oct 18, 2021, 4:16 PM ET
CytoDyn Alerts Shareholders to Vote on Company’s Proxy Card Ahead of October 28 th
Other events · EX-99.1 to Form 8-K
Oct 14, 2021, 5:05 PM ET
Delaware Court Agrees with CytoDyn that Activist Group’s Nominations are Invalid
Other events · EX-99.1 to Form 8-K